Abbott denies FT speculation about a St. Jude's acquisition.» Read More
CNBC's Steve Liesman reports how participants of CNBC's All-America Economic Survey view Obamacare, and raising the minimum wage.
CNBC's Steve Liesman reports 56 percent of participants supported the legalization of marijuana in their town.
The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.
Senator Nicholas Scutari, D-N.J., discusses the bill he introduced that would allow adults to purchase and grow a limited amount of marijuana for personal use in New Jersey.
CNBC's Sheila Dharmarajan reports 15 percent of high school aged children are diagnosed with ADHD, or attention deficit hyperactivity disorder.
Dr. Richard Saul wrote a book called "ADHD Does Not Exist." Saul is certain attention ADHD, or attention deficit hyperactivity disorder exists only in its symptoms. The condition does not exist.
Costco Wholesale's profit fell 15 percent, missing estimates, hurt by weaker gross margins in its fresh-food business and some non-foods merchandises.
Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.
Starbuds of Denver owner Brian Ruden says the next step in his business is to get more "growth capacity" to handle the demand.
InterMune president & CEO Dan Welch says positive drug trial results bring hope to patients with idiopathic pulmonary fibrosis, and discusses the volatility in its stock.
CNBC's Morgan Brennan reports the pharmaceutical companies are developing oral therapies for the condition that could replace current treatments.
At least one analyst at Target pushed for an investigation into payment systems after government and industry reports.
NBC's Pete Williams reports the government has issued guidance for banks servicing legal marijuana businesses. CNBC's Jane Wells provides insight.
Global healthcare company Roche is confident of growth in emerging markets despite the economic slowdown.
Companies and industries that rely on low-income spenders could see a boost to the bottom line thanks to rising wages in many American states.
Michael Morrissey, Exelixis president & CEO, provides insight on clinical research of prostate cancer and its cancer drug Cometriq.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
Eli Lilly Chairman & CEO John Lechleiter provides insight on its rights to an experimental migraine drug.
Eli Lilly Chairman & CEO John Lechleiter discusses its loss of major patents, its current pipeline and when its total costs will normalize.
CNBC's Morgan Brennan reports on the FDA's four expediting pipelines. The approval rates for the drugs in these pipelines tend to be higher than those plodding the more traditional course.